NCT04587128 2026-02-05
Early-Line Anti-EGFR Therapy to Facilitate Retreatment for Select Patients With mCRC
University of Wisconsin, Madison
Phase 2 Active not recruiting
Clinical Trials
58 trialsNCT04787341 2026-02-02
PARERE
Gruppo Oncologico del Nord-Ovest
Phase 2 Active not recruiting
NCT03087071 2026-01-12
Panitumumab With or Without Trametinib in Treating Patients With Stage IV Colorectal Cancer
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT03366155 2026-01-08
Hepatic Artery Infusion Pump Chemotherapy With Floxuridine and Dexamethasone in Combination With Systemic Chemotherapy for Patients With Colorectal Cancer Metastatic to the Liver
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT03983993 2026-01-05
NIPAVect
Emory University
Phase 2 Active not recruiting
NCT06714357 2025-12-17
VICTORIA
National Cancer Institute, Naples
Phase 2 Recruiting
NCT06245356 2025-12-10
TRIFLUOX-DP
UNICANCER
Phase 2 Recruiting
NCT05576896 2025-10-20
Hydroxychloroquine in Combination With Encorafenib and Cetuximab or Panitumumab in the Treatment of Metastatic BRAF-mutated Colorectal Cancer Refractory
Northwestern University
Phase 2 Recruiting
NCT01312857 2025-10-09
Study of Hepatic Arterial Infusion With Intravenous Irinotecan, 5FU and Leucovorin With or Without Panitumumab, in Patients With Wild Type RAS Who Have Resected Hepatic Metastases From Colorectal Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT03186326 2025-06-29
SAMCO
Federation Francophone de Cancerologie Digestive
Phase 2 Completed
NCT03584711 2025-06-29
OPTIPRIME
Federation Francophone de Cancerologie Digestive
Phase 2 Completed
NCT06978400 2025-05-18
A Study of Dabrafenib Plus Cetuximab/Panitumumab With FOLFOX in the First Line of Therapy in People With Metastatic Colorectal Cancer
Blokhin's Russian Cancer Research Center
Phase 2 Recruiting
NCT04117945 2024-09-27
Regorafenib, With Cetuximab or Panitumumab, for the Treatment of Unresectable, Locally Advanced, or Metastatic Colorectal Cancer
Academic and Community Cancer Research United
Phase 2 Active not recruiting
NCT00891930 2024-07-17
Study to Evaluate Mechanisms of Acquired Resistance to Panitumumab
NantBioScience, Inc.
Phase 2 Completed
NCT03992456 2024-05-21
Panitumumab, Regorafenib, or TAS-102, in Treating Patients With Metastatic and/or Unresectable RAS Wild-Type Colorectal Cancer
Academic and Community Cancer Research United
Phase 2 Active not recruiting
NCT01776307 2023-11-15
A Study of BBI608 in Adult Patients With Advanced Colorectal Cancer
Sumitomo Pharma America, Inc.
Phase 2 Completed
NCT01328171 2023-06-15
VOLFI
AIO-Studien-gGmbH
Phase 2 Completed
NCT01991873 2023-06-15
PanaMa
AIO-Studien-gGmbH
Phase 2 Completed
NCT01801904 2023-03-24
PACER
National Cancer Institute, Naples
Phase 2 Unknown
NCT00819780 2022-12-06
PEAK: Panitumumab Plus mFOLFOX6 vs. Bevacizumab Plus mFOLFOX6 for First Line Treatment of Metastatic Colorectal Cancer (mCRC) Patients With Wild-Type Kirsten Rat Sarcoma-2 Virus (KRAS) Tumors
Amgen
Phase 2 Completed
NCT00089635 2022-11-07
Panitumumab (ABX-EGF) Monotherapy in Patients With Metastatic Colorectal Cancer
Amgen
Phase 2 Completed
NCT03227926 2022-08-25
CHRONOS
Fondazione del Piemonte per l'Oncologia
Phase 2 Completed
NCT02399943 2022-05-16
A Trial of Trametinib and Panitumumab in RAS/RAF Wild Type Advanced Colorectal Cancer
University Health Network, Toronto
Phase 2 Completed
NCT04425239 2022-04-07
IMPROVE
National Cancer Institute, Naples
Phase 2 Completed
NCT03142516 2021-06-21
OPALO
Grupo Espanol Multidisciplinario del Cancer Digestivo
Phase 2 Completed
NCT02448810 2021-05-25
Phase 2a Study of BAX69 and 5-FU/Leucovorin or Panitumumab Versus Standard of Care in Subjects With Metastatic Colorectal Cancer
Takeda
Phase 2 Terminated
NCT04668976 2020-12-21
A Study of the Use of the Medtronic Pump and Codman Catheter to Give Chemotherapy to Patients With Colorectal Carcinoma or Cholangiocarcinoma
Benaroya Research Institute
Phase 2 Unknown
NCT01057017 2020-02-17
First-Line FOLFOX-Bevacizumab for Advanced Colorectal Cancer With Wild-Type Ras
Brown University
Phase 2 Terminated
NCT00508404 2019-11-19
Panitumumab Plus FOLFIRI in First-line Treatment of Metastatic Colorectal Cancer
Amgen
Phase 2 Completed
NCT02337946 2019-09-10
SAPPHIRE
Takeda
Phase 2 Completed
NCT04034173 2019-07-26
Optimal Anti-EGFR Treatment of mCRC Patients With Low-Frequency RAS Mutation
Ludwig-Maximilians - University of Munich
Phase 2 Not yet recruiting
NCT01260415 2019-05-14
A Study of Perioperative Chemotherapy Plus Panitumumab in Patients With Colorectal Cancer Liver Metastases
University Health Network, Toronto
Phase 2 Completed
NCT00940316 2019-05-07
Dual Epidermal Growth Factor Receptor Inhibition With Erlotinib and Panitumumab With or Without Chemotherapy for Advanced Colorectal Cancer
Northwestern University
Phase 2 Completed
NCT00418938 2018-10-17
SPIRITT - Second-Line Panitumumab Irinotecan Treatment Trial
Amgen
Phase 2 Completed
NCT02508077 2018-08-16
FOLFIRI and Panitumumab in Treating Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer
City of Hope Medical Center
Phase 2 Terminated
NCT01288339 2018-05-16
PULSE
Grupo Espanol Multidisciplinario del Cancer Digestivo
Phase 2 Completed
NCT01704703 2017-08-01
ULTRA
Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)
Phase 2 Completed
NCT00842257 2017-05-16
Panitumumab in Cetuximab Refractory KRAS Wild-Type Colorectal Cancer
Massachusetts General Hospital
Phase 2 Completed
NCT02476045 2016-09-14
Valentino
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Phase 2 Unknown
NCT00332163 2016-02-23
STEPP
Amgen
Phase 2 Completed
NCT00411450 2016-02-15
PRECEPT
Amgen
Phase 2 Completed
NCT01226719 2015-05-27
FOLFOXIRI Plus Panitumumab Patients With Metastatic KRAS Wild-Type Colorectal Cancer With Liver Metastases Only
SCRI Development Innovations, LLC
Phase 2 Completed
NCT01126112 2015-03-24
FRAIL
Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)
Phase 2 Completed
NCT01215539 2015-03-18
Study of Panitumumab-Capecitabine-Oxaliplatin In Wild-Type K-Ras Metastatic Colorectal Cancer Patients
Hellenic Cooperative Oncology Group
Phase 2 Completed
NCT00814619 2014-04-30
Capecitabine and Radiation Therapy With or Without Panitumumab in Treating Patients With Advanced Rectal Cancer
Swiss Cancer Institute
Phase 2 Completed
NCT00083616 2014-01-10
Evaluating Panitumumab (ABX-EGF) Monotherapy in Patients With Metastatic Colorectal Cancer Following Treatment With Fluoropyrimidine, Irinotecan, and Oxaliplatin Chemotherapy
Amgen
Phase 2 Completed
NCT00967655 2014-01-10
Capecitabine, Panitumumab, and Radiation Therapy With or Without Irinotecan Hydrochloride in Treating Patients Undergoing Surgery for Localized Rectal Cancer
National Cancer Institute (NCI)
Phase 2 Unknown
NCT01110785 2013-09-17
Simvastatin and Panitumumab in Treating Patients With Advanced or Metastatic Colorectal Cancer
National Cancer Institute (NCI)
Phase 2 Unknown
NCT00475293 2013-09-13
Panitumumab in Combination With Irinotecan Chemotherapy as 2nd-line Therapy in Subjects With mCRC
Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)
Phase 2 Completed
NCT00111774 2013-05-14
Evaluating ABX-EGF in Patients With Metastatic ColorectalCarcinoma
Amgen
Phase 2 Completed